Alzheimer's Disease/Cognition News

Higher education levels may protect against cognitive and functional difficulties for Black individuals with high levels of tau, indicating Alzheimer’s pathology, according to research from the Journal of Alzheimer’s Disease.

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

The FDA will convene an advisory committee meeting to discuss the safety and efficacy of donanemab in early symptomatic Alzheimer's disease, according to the manufacturer.

The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.

Quanterix Corp. has announced collaborations with several health systems with the goal of improving and simplifying Alzheimer’s disease diagnosis by expanding access to blood biomarker assays.

RetinalGeniX Technologies has been granted a patent for its System and Method for Visualization of Ocular Anatomy, designed to aid in diagnosis of ocular and systemic diseases, according to a company press release.

Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.